Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

955 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer.
Campbell MT, Shah AY, Msaouel P, Tannir NM, Siefker-Radtke AO, Kamat AM, Navai N, Dinney CPN, Rao P, Guo CC, Sheth RA, Venkatesan AM, Tidwell RS, Yadav SS, Gu A, Chen H, Macaluso M, Duan F, Basu S, Jindal S, Sharma P. Campbell MT, et al. Among authors: jindal s. Cancer Res Commun. 2024 Sep 1;4(9):2444-2453. doi: 10.1158/2767-9764.CRC-24-0237. Cancer Res Commun. 2024. PMID: 39207194 Free PMC article.
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma.
Campbell MT, Matin SF, Tam AL, Sheth RA, Ahrar K, Tidwell RS, Rao P, Karam JA, Wood CG, Tannir NM, Jonasch E, Gao J, Zurita AJ, Shah AY, Jindal S, Duan F, Basu S, Chen H, Espejo AB, Allison JP, Yadav SS, Sharma P. Campbell MT, et al. Among authors: jindal s. Nat Commun. 2021 Nov 4;12(1):6375. doi: 10.1038/s41467-021-26415-4. Nat Commun. 2021. PMID: 34737281 Free PMC article. Clinical Trial.
Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment.
Subudhi SK, Siddiqui BA, Aparicio AM, Yadav SS, Basu S, Chen H, Jindal S, Tidwell RSS, Varma A, Logothetis CJ, Allison JP, Corn PG, Sharma P. Subudhi SK, et al. Among authors: jindal s. J Immunother Cancer. 2021 Oct;9(10):e002919. doi: 10.1136/jitc-2021-002919. J Immunother Cancer. 2021. PMID: 34663638 Free PMC article.
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy.
Msaouel P, Goswami S, Thall PF, Wang X, Yuan Y, Jonasch E, Gao J, Campbell MT, Shah AY, Corn PG, Tam AL, Ahrar K, Rao P, Sircar K, Cohen L, Basu S, Duan F, Jindal S, Zhang Y, Chen H, Yadav SS, Shazer R, Der-Torossian H, Allison JP, Sharma P, Tannir NM. Msaouel P, et al. Among authors: jindal s. Sci Transl Med. 2022 Apr 20;14(641):eabm6420. doi: 10.1126/scitranslmed.abm6420. Epub 2022 Apr 20. Sci Transl Med. 2022. PMID: 35442707 Clinical Trial.
Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade.
Goswami S, Raychaudhuri D, Singh P, Natarajan SM, Chen Y, Poon C, Hennessey M, Tannir AJ, Zhang J, Anandhan S, Kerrigan BP, Macaluso MD, He Z, Jindal S, Lang FF, Basu S, Sharma P. Goswami S, et al. Among authors: jindal s. Nat Cancer. 2023 Oct;4(10):1455-1473. doi: 10.1038/s43018-023-00620-0. Epub 2023 Aug 31. Nat Cancer. 2023. PMID: 37653141
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer.
Aparicio AM, Tidwell RSS, Yadav SS, Chen JS, Zhang M, Liu J, Guo S, Pilié PG, Yu Y, Song X, Vundavilli H, Jindal S, Zhu K, Viscuse PV, Lebenthal JM, Hahn AW, Soundararajan R, Corn PG, Zurita-Saavedra A, Subudhi SK, Zhang J, Wang W, Huff C, Troncoso P, Allison JP, Sharma P, Logothetis CJ. Aparicio AM, et al. Among authors: jindal s. Clin Cancer Res. 2024 Jul 1;30(13):2751-2763. doi: 10.1158/1078-0432.CCR-23-3740. Clin Cancer Res. 2024. PMID: 38683200 Clinical Trial.
TSG-6+ cancer-associated fibroblasts modulate myeloid cell responses and impair anti-tumor response to immune checkpoint therapy in pancreatic cancer.
Anandhan S, Herbrich S, Goswami S, Guan B, Chen Y, Macaluso MD, Jindal S, Natarajan SM, Andrewes SW, Xiong L, Nagarajan A, Basu S, Tang DN, Liu J, Min J, Maitra A, Sharma P. Anandhan S, et al. Among authors: jindal s. Nat Commun. 2024 Jul 10;15(1):5291. doi: 10.1038/s41467-024-49189-x. Nat Commun. 2024. PMID: 38987547 Free PMC article.
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.
Kaseb AO, Hasanov E, Cao HST, Xiao L, Vauthey JN, Lee SS, Yavuz BG, Mohamed YI, Qayyum A, Jindal S, Duan F, Basu S, Yadav SS, Nicholas C, Sun JJ, Singh Raghav KP, Rashid A, Carter K, Chun YS, Tzeng CD, Sakamuri D, Xu L, Sun R, Cristini V, Beretta L, Yao JC, Wolff RA, Allison JP, Sharma P. Kaseb AO, et al. Among authors: jindal s. Lancet Gastroenterol Hepatol. 2022 Mar;7(3):208-218. doi: 10.1016/S2468-1253(21)00427-1. Epub 2022 Jan 20. Lancet Gastroenterol Hepatol. 2022. PMID: 35065057 Free PMC article. Clinical Trial.
Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by interleukin-6 blockade.
Baruch EN, Nagarajan P, Gleber-Netto FO, Rao X, Xie T, Akhter S, Adewale A, Shajedul I, Mattson BJ, Ferrarotto R, Wong MK, Davies MA, Jindal S, Basu S, Harwood C, Leigh I, Ajami N, Futreal A, Castillo M, Gunaratne P, Goepfert RP, Khushalani N, Wang J, Watowich S, Calin GA, Migden MR, Vermeer P, D'Silva N, Yaniv D, Burks JK, Gomez J, Dougherty PM, Tsai KY, Allison JP, Sharma P, Wargo J, Myers JN, Gross ND, Amit M. Baruch EN, et al. Among authors: jindal s. Res Sq [Preprint]. 2023 Jul 18:rs.3.rs-3161761. doi: 10.21203/rs.3.rs-3161761/v1. Res Sq. 2023. PMID: 37503252 Free PMC article. Preprint.
955 results